AnaptysBio, Inc.
ANAB
Updated: 24/09/2026, 08:10:56
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
No summaries found.
- Share price
- $50.77
- Market cap
- $1.50B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Daniel Faga
- Employees
- 104
- IPO date
- 26/01/2017
- Beta
- 0.408
- Last dividend
- $0.00
- Day range
- $49.45 – $53.93
- 52-week range
- $13.86 – $72.36
- 1-day performance
- -5.84%
- 1-year performance
- 266.31%
- Current drawdown (1Y)
- -29.84%
- CIK
- 0001370053
- CUSIP
- 032724106
- ISIN
- US0327241065
- Created
- 07/12/2025, 02:05:24
- Last update
- 24/09/2026, 08:10:56
Track AnaptysBio, Inc. with an AI analyst
See which prediction-market events move ANAB, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
AnaptysBio, Inc. (NASDAQ:ANAB) Shows Strong Capital Efficiency
Market Data • Market Data • 22/05/2026, 22:00:06
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
Zacks Investment Research • STOCK • 21/05/2026, 12:40:32
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?
Zacks Investment Research • STOCK • 19/05/2026, 12:55:45
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks Investment Research • STOCK • 14/05/2026, 12:55:42
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
GlobeNewsWire • STOCK • 11/05/2026, 11:15:00
AnaptysBio (NASDAQ: ANAB) Faces Legal Uncertainty Amidst Upcoming Earnings and Financial Scrutiny
Market Data • Market Data • 09/05/2026, 12:00:10
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
Zacks Investment Research • STOCK • 05/05/2026, 12:41:32
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
GlobeNewsWire • STOCK • 04/05/2026, 18:15:00
AnaptysBio (ANAB) Business Model Shift, Earnings & Stock Surge
Market Data • Market Data • 01/05/2026, 19:00:13
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Zacks Investment Research • STOCK • 27/04/2026, 13:02:05
AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?
Zacks Investment Research • STOCK • 27/04/2026, 11:20:24
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim
GlobeNewsWire • STOCK • 24/04/2026, 17:40:00